RT Journal Article
SR Electronic
T1 Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Copper-67
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.120.251579
DO 10.2967/jnumed.120.251579
A1 Lachlan E. McInnes
A1 Carleen Cullinane
A1 Peter Roselt
A1 Susan Jackson
A1 Benjamin Blyth
A1 Ellen van Dam
A1 Nicholas A. Zia
A1 Matthew J. Harris
A1 Rodney J. Hicks
A1 Paul S. Donnelly
YR 2020
UL http://jnm.snmjournals.org/content/early/2020/10/23/jnumed.120.251579.abstract
AB Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising treatment for prostate cancer. We reported a ligand featuring two lysine-ureido-glutamate groups, 64Cu-CuSarbisPSMA previously. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated following treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA I&T. Results: At 13 days post-injection, tumor growth was similarly inhibited by the two tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated administrations (2 x 15MBq, two weeks apart). Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.